Sarepta (SRPT) EVP & General Counsel has shares withheld for RSU taxes
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Sarepta Therapeutics EVP and General Counsel Cristin Rothfuss reported a small share disposition for tax withholding purposes. On March 2, 2026, 408 shares of Sarepta common stock were withheld by the company at $16.20 per share to cover taxes on restricted stock units that vested from a grant made on March 1, 2024. After this tax-withholding transaction, Rothfuss’s directly held ownership stood at 139,348 shares of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Rothfuss Cristin
Role
EVP, General Counsel
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 408 | $16.20 | $7K |
Holdings After Transaction:
Common Stock — 139,348 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did Sarepta Therapeutics (SRPT) report for Cristin Rothfuss?
Sarepta reported that EVP and General Counsel Cristin Rothfuss had 408 common shares withheld on March 2, 2026 to satisfy tax obligations on vested restricted stock units. This is a tax-withholding disposition rather than an open-market share sale.
What type of insider transaction code is shown in the Sarepta (SRPT) Form 4?
The Form 4 uses transaction code F, which indicates payment of tax liability or exercise price by delivering securities. In this case, 408 shares of Sarepta common stock were withheld to cover taxes on vested restricted stock units held by Cristin Rothfuss.